KRAS and colorectal carcinoma: Key genetic alterations in CRC patients with prognostic value involve a mutant v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), the most common RAS mutation, which between 30% and 50% of CRC patients express [11,12].